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Overexpression of the epidermal growth factor receptor-related gene ErbB2 occurs in 18% to 25% of patients with
breast cancer in Western countries and is associated with a poor prognosis. The prevalence of ErbB2-positive tumors
in Asia is unclear, partly because data are limited. The objective of this review was to summarize the reported preva-
lence of ErbB2-positive tumors from a large sample of Asian patients and to examine ErbB2 assessment methods in
Asia. From searches of MEDLINE, local language journals, and local and international conference proceedings as well
as locoregional breast cancer experts’ recommendations, the authors selected up to 5 studies each from India, Korea,
Malaysia, the Philippines, Singapore, Taiwan, and Thailand that reported ErbB2 results based on assessment with
immunohistochemistry (IHC) and/or fluorescence in situ hybridization (FISH). The reported prevalence of ErbB2-posi-
tive tumors in 22 studies on 24,671 patients, of whom 14,398 patients were assessed for ErbB2 status, varied widely
(range, 6%-65%) as did the assessment methods used. Most studies (n ¼ 21) used IHC to assess ErbB2 status, but
definitions for positivity varied. When robust assessment methods were used, the median prevalence was 19% based
on strong IHC staining (IHC3þ;n¼ 9812 patients) and 25% based on FISH (n ¼ 681 patients). Data on the prevalence
of ErbB2-positive breast cancer in Asia are limited. The current survey indicated that the prevalence in Asia may be
similar to that in Western countries; thus, up to 1 in 4 Asian patients with breast cancer potentially could benefit from
ErbB2-targeted treatment. A standard, reliable ErbB2 assessment method available to patients across Asia is
urgently required. Cancer 2010;116:5348–57. V C 2010 American Cancer Society.
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Although the incidence of breast cancer in some Western countries has fallen recently, its incidence still is increasing
in Asia.
1,2 Furthermore, thesurvival rate amongpatients withbreastcancer in Asia is approximately half thatof patients in
Westerncountries.
2,3These observationsaredriving interestin gainingabetterunderstanding of breastcancer inAsia.
Studies from Western countries indicate that breast cancer survival is low in patients with tumors that over express
the human epidermal growth factor receptor-related gene ErbB2 (c-ErbB2, HER2,o rneu).
4,5 Tumors that over express
ErbB2 are more likely to recur
4,5 and are relatively resistant to many treatments.
4 Two recently developed treatments that
specificallytargetErbB2,trastuzumabandlapatinib,areeffectiveeitheraloneorwithchemotherapyinreducingtumorre-
currence andmortalityinpatientswithErbB2-positivebreastcancer.
6
GiventheincreasingincidenceofbreastcancerinAsiaandtheclinicalconsequences ofErbB2-positivebreastcancer,
insightinto theprevalenceofErbB2-positivetumorsinAsiais important.Recently,2largestudiesofbreastcancer registry
dataintheUnitedStatesreportedthatwomenofAsiandescentweremorelikelytohaveErbB2-positivetumorsthanCau-
casian women,
7,8 suggesting possible racial differences. Whether the prevalence of ErbB2-positive breast cancer differs
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Review Articlebetween Asian and Western countries requires clarifica-
tion. A higher prevalence of ErbB2-positivity may be 1 of
several factors contributing to the lower survival rate of
Asianbreastcancerpatients.
Because ErbB2 status is assessed by different meth-
ods (by immunohistochemistry [IHC] or, less commonly,
by fluorescence in situ hybridization [FISH]
9), it is also
important to know how ErbB2 is assessed within different
Asiancountries. Theaccurate estimation of the prevalence
of ErbB2-positive tumors in Asia has been hindered by
variability in both the availability of assessment methods
and the definition of ErbB2 positivity. In addition, data
on ErbB2 positivity in Asia are limited in the literature
that can be searched electronically (eg, in the MEDLINE
database).
To gain insight into the prevalence and assessment of
ErbB2-positive breast cancer in Asia through a literature sur-
vey, we formed the Early Breast Cancer Working Group
(EBCWG). Because we anticipated that it would be a chal-
lenge to find data on ErbB2 prevalence in Asia, we also
engaged with our peers who were familiar with relevant
researchinourcountries.Theobjectivesofourliteraturesur-
v e yw e r et os u m m a r i z et h er e p o r t e dp r e v a l e n c eo fE r b B 2 -
positive breast cancer in 7 Asian countries and to examine
the ErbB2assessmentmethodsusedinthesecountries.
MATERIALS AND METHODS
Literature Search Strategy
After the initial EBCWG meeting, we conducted separate
literature searches for our respective countries (India,
Korea, Malaysia, the Philippines, Singapore, Taiwan, and
Thailand). We obtained relevant literature from searches
of the MEDLINE database using PubMed (2000 to
September 2008) with the search terms (ErbB2 OR HER2
OR ErbB-2 OR HER-2) AND ‘‘breast cancer’’ AND
(countryofinterest). We alsosearched, either electronically
or by hand, local language journals and the proceedings of
local and international oncology conferences, and we con-
sulted with our professional networks for access to results
from recent studies. Because the availability and quality of
ErbB2 assessment in Asian clinics increased after the ap-
proval of trastuzumab in 2000, we limited our searches to
studiesthatwerepublishedduringorafter2000.
Study Selection Criteria
We selected studies that reported the results of ErbB2
assessment by IHC, FISH, or both for further review. To
focus on clinical ErbB2 assessment in our countries, we
excluded studies of Asian patients who were living in
Western countries and studies that reported serum, mes-
senger RNA, or cell line ErbB2 data. For each country, we
selected up to 5 studies for detailed review. Preference was
given to studies that had large sample sizes, multicenter
studies, and studies that were published in higher impact
factorjournals.
Data Analysis
The EBCWG met again to analyze data from the selected
studies. We divided the ErbB2 prevalence data from the
studies into 3 categories based on the testing and grading
methods used for assessment: 1) IHC combined or not
specified, ie, IHC with intermediate (IHC2þ) and strong
(IHC3þ) staining combined or IHC with no grading
method specified; 2) IHC3þ only; and 3) FISH. Then, we
calculated the median and mean ( standard deviation)
prevalenceofErbB2-positivetumorsineachcategory.
We hypothesized that lower income countries may
report higher ErbB2þ prevalence rates because of the lim-
ited availability of robust, but expensive, assay methods
(eg, FISH). We used a 2-sample t test (assuming unequal
variances) to compare differences between low/middle-
income countries and high-income countries in the
reported ErbB2þ prevalence rates assessed with IHC2þ/
IHC3þ combined or not specified, IHC3þ only, or
FISH. Countries were classified as low, middle, or high
income based on the 2007 World Bank income classifica-
tion (available at: http://data.worldbank.org/about/coun-
try-classifications/a-short-historyaccessed July23,2010).
RESULTS
Summary of Selected Literature
We selected 22 studies (see Table 1), including 17 publi-
cations
10-26 and 5 conference abstracts,
27-31 for further
review. For Malaysia
30,31 and the Philippines,
29 only con-
ferenceabstractsmetourselectioncriteria.
Patients Assessed for ErbB2
Our selected studies included 24,671 patients, including
14,398 patients (58.4%) who were assessed for ErbB2
(Table 1). The number of patients in each study ranged
from 63 patients
11 to 9668 patients,
24 and the number
assessed for ErbB2 ranged from 63 patients
11 to 4319
patients.
24 The ageof patients varied widely (range,19-89
years) among those studies in which it was reported; how-
ever, most patients were in their 40s or 50s. Most patients
(10,203 of 13,171 patients; 77.5%) for whom cancer
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Cancer December 1, 2010 5349Table 1. Description of 22 Studies Reporting Human Epidermal Growth Factor Receptor-Related Gene 2-Positive Breast Cancer in
Asia
Sampling Patients (%)
Study and Design No. Setting Dates Age Stage or Grade
a
India
Bhamrah 2008
27;
observational
210 All India Institute of
Medical Sciences
NR NR NR
Meenakshi 2003
17;
prospective,
observational
127 Cancer Institute NR NR NR
Korea
Kim 2006
14;
retrospective,
observational
776 Asan Medical Center 1993-1998 Mean, 47.4 y;
range, 24-88 y
Stage: I, 182 (23.5);
II, 336 (47.2);
III, 225 (29);
IV, 3 (0.4)
Korean Breast Cancer
Society, 2006
24;
retrospective,
observational
Total, 9668;
ErbB2-
tested, 4318
Medical schools, 39;
hospitals, 27;
private clinics, 7
2004 Age known: 8376;
median, 47 y;
 29 y, 157 (1.9);
30-39 y, 1409 (16.8);
40-49 y, 3452 (41.2);
50-59 y, 1987 (23.7);
60-69 y, 1017 (12.1);
 70 y, 354 (4.2)
Total assessed,
5301 (100);
Stage: 0, 508 (9.6);
I, 1889 (35.6);
II, 2062 (38.9);
III, 772 (14.6);
IV, 70 (1.3)
Park 2003
19;
prospective,
observational
188 University Sanggye
Paik Hospital
NR NR Histologic grade
b:
1, 22 (11.7);
2. 83 (44.1);
3. 73 (38.8);
unknown: 10 (5.3)
Park & Han 2004
18;
observational
Samples in
TMA, 132-261
Inje University Sanggye
Paik Hospital
NR NR NR
Shin 2006
22;
retrospective,
observational
Total, 4063;
ErbB2-
tested, 2196
Seoul National
Universiti
Hospital
1981-2002 Median, 46 y;
 29 y, 163 (4);
30-39 y, 983 (24.2);
40-49 y, 1572 (38.7);
50-59 y, 921 (22.7);
60-69 y, 334 (8.2);
 70 y, 79 (1.9);
unknown, 16 (0.4)
c
Total assessed,
3761 (100);
Stage: 0, 175 (4.7);
I, 1042 (27.7);
II, 1652 (43.9);
III, 726 (19.3);
IV, 166 (4.4)
Malaysia
Shahrun 2008
30;
retrospective,
observational
300 International Islamic
University Malaysia;
Universiti
Kebangsaan
Malaysia
2003-2007 NR NR
Tan &Yip 2008
31;
prospective,
observational
393 University Malaya
Medical Center
2007 <40 y (12);
 40 y (88)
Stage: 0, 11 (2.7);
I, 98 (24.8);
II, 189 (48.2);
III, 61 (15.5);
IV, 34 (8.7)
Singapore
Fernandopulle 2006
12;
retrospective,
observational
112 Singapore General
Hospital
1993-2004 All,  35 y; mean,
29.1 y; median, 30 y;
range, 19-35 y
Histologic grade
d:
1, 7 (6.3);
2, 24 (21.4);
3, 54 (48.2);
unknown, 27 (24.1)
Selvarajan 2006
20;
retrospective,
observational
184 Singapore General
Hospital
1998-2002 NR NR
Selvarajan 2006
21;
retrospective,
observational
321 Singapore General
Hospital
1998-2002  50 y; 134 (41.7);
>50 y, 181 (56.4);
unknown, 6 (1.9)
Stage: I, 68 (21.2);
II, 102 (61.8);
III, 23 (13.9);
IV, 5 (3)
(Continued)
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Sampling Patients (%)
Study and Design No. Setting Dates Age Stage or Grade
a
Tan 2008
23;
retrospective,
observational
165 National Cancer
Centre Tissue
Repository
2000-2004 Mean SD, 56 12 y;
range, 30-79 y;
 54 y, 82 (49.7);
>54 y, 83 (50.3)
Stage: I, 36 (21.8);
II, 192 (59.8);
III, 28 (8.7);
IV, 7 (2.2);
unknown, 26 (8.1)
e
Zhang 2003
26;
retrospective,
observational
97 National University
Hospital
NR NR Histologic grade
f:
1, 9 (9.3);
2, 34 (35.1);
3, 44 (45.4);
unknown, 10 (10.3)
Taiwan
Chen 2008
11;
open label,
phase 2 trial
63 Chang Gung
Memorial Hospital
2002-2005 Median, 46 y; range,
29-69 y
Tumor classification:
T2, 25 (39.7);
T3, 32 (50.8);
T4, 6 (9.5)
Huang 2008
13;
prospective
pilot trial
192 Kaohsiung Medical
University Hospital
2003-2005 Median SD,
48.9 9.6 y;
<50 y, 112 (58.3);
 50 y, 80 (41.7)
Stage: II,
160 (83.3);
III, 32 (16.7)
Lin 2007
16; Phase 2
randomized
controlled trial
101 Chang Gung Memorial
Hospital
2000-2002 Median, 48 y; range,
25-70 y
All stage IV
Lin 2009
15;
prospective,
observational
1028 National Taiwan University
Hospital
2004-2006 Median, 50 y; range,
23-88 y
Stage: I, 316 (30.7);
II, 417 (45.8);
III, 176 (17.1);
IV, 52 (5.1);
unknown, 13 (1.3)
Tsai 2001
25;
retrospective,
observational
167 Kaohsiung Medical
University Hospital
1990-1999 Mean age:
Familial, 47.8 y,
n¼56; nonfamilial,
50.1 y, n¼111
Histologic grade
g:
1, 13 (7.8);
2, 51 (30.5);
3, 63 (37.7);
unknown, 40 (24)
Thailand
Chearskul 2001
10;
retrospective,
observational
506 Siriraj Hospital 1992-2000 Mean age, 50.8 y;
range, 24-89 y;
 50 y, 246 (48.6);
>50 y, 255 (50.4);
unknown, 5 (1)
I, 50 (9.9);
II, 366 (72.3);
III, 60 (11.9);
IV, 5 (1);
unknown, 25 (4.9)
Moohamad 2008
28;
retrospective,
observational
442 Phramongkutklao
Hospital
2003-2006 NR NR
The Philippines
Sanchez 2007
29;
retrospective,
observational
Total, 5307;
ErbB2-
tested, 2333
St. Luke’s Medical
Center
1994-2004 NR NR
NR indicates not reported; ErbB2, human epidermal growth factor receptor-related gene 2; TMA, tissue microarray; SD, standard deviation.
aAmerican Joint Committee on Cancer stages unless otherwise noted.
bNottingham histologic grading system.
cPercentages listed were calculated on a total of 4063 patients, as reported by the article. Note: number of patients listed by age in the article actually totals
4068.
dUnited Kingdom National Health System grading system.
eThe number of patients listed by tumor stage in the article totals 166, not 165. Percentages listed here were calculated based on a total of 165 patients.
fTumor grades were stated in the article, but the grading system was not specified.
gModified Bloom-Richardson grading system.
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¼ 694 [5.3%]; stage I, n ¼ 3732 [28.3%]; stage II, n ¼
5777[43.9%]).
Prevalence of ErbB2-Positive Breast Cancer
The prevalence of ErbB2-positive breast cancer in Asia
was influenced by the testing method and grading criteria
used (Tables 2 and 3). Generally, prevalence results were
lowest with IHC when positivity was defined as IHC3þ,
intermediate withFISH,and highestwithIHCwhen pos-
itivity was defined as IHC2þ and IHC3þ combined or
when positivity was not defined. When the results
obtained using any of the assessment methods were exam-
ined, the prevalence of ErbB2-positive breast cancer var-
ied widely (range, 6%-65%). When results were limited
to those obtained with the more robust methods
(IHC3þ, FISH), the median prevalence was 19% and
25%, respectively (Fig. 1). Even with this narrower
focus, these results were obtained from 10,076 patients
in 5 Asian countries (India, Korea, Singapore, Taiwan,
and the Philippines). The least variable results were
obtained with the less common assessment method,
FISH(Table 3).
The mean prevalence of ErbB2-positive tumors was
similar to the median prevalence for all 3 assessment
methods (Table 3). Omitting the maximum and mini-
mum prevalence values did not change the mean mark-
edly (IHC2þ/IHC3þ combined or not specified ¼
32.6% vs an actual rate of 33.7%; IHC3þ only ¼ 19.4%
vs anactualrate of20.4%).
When prevalence data from high-income (Korea,
Singapore, and Taiwan) and low or middle-income
(India, Malaysia,Thailand, and the Philippines)countries
were compared, there was no significant difference (P ¼
.82) in the mean prevalence when positivity was defined
as IHC2þ/IHC3þ or when the definition was not speci-
fied. Similarly, there was no significant difference (P ¼
.59) in the mean prevalence when positivity was defined
as IHC3þ. The similarity in prevalence results between
high-income and low or middle-income countries also
was apparent from a comparison of the median values for
IHC (Fig. 1). No comparison could be made for studies
using FISH, because none of the studies from low or mid-
dle-income countries used this method. Among the coun-
tries in our survey, only high-income countries (ie, Korea,
Singapore, and Taiwan) routinely tested for ErbB2 status
andsubsidizedthecostoftrastuzumabforeligiblepatients
(Table4).
ErbB2 Assessment Methods
The most common ErbB2 assessment method was IHC,
which was used in 21 of 22 studies (95.5%). Although 12
studies providedthe name and/or supplier of the antibody
used, 7 studies (including the 5 conference abstracts) did
not specify either. The most commonly used antibodies
were from Dako (Glostrup, Denmark), including 4 stud-
ies that used the HercepTest (Dako), 2 studies that used
the A0485 rabbit polyclonal antibody, and 4 studies that
used unspecified Dako antibodies. Only 4 stud-
ies
18,19,26,31 from 2 countries (Korea and Singapore) used
FISH to assess ErbB2, whereas 1 study from Taiwan
15
used FISH to confirm ErbB2 positivity in tumors with
IHC2þ staining.
DISCUSSION
On the basis of the ErbB2 assessment results from 14,398
patients in 7 Asian countries, our literature survey indi-
cated that the reported prevalence of ErbB2-positive
breast cancer has varied from 6% to 65%. However,when
ErbB2 was assessed robustly using IHC3þ or FISH, the
median prevalence, based on the results from 10,076
Asian patients in 5 countries, was 19% with IHC3þ and
25% with FISH. These prevalence results are similar to
those in Western countries.
4,5 Because ErbB2 status is
predictive for both prognosis and therapeutic response,
knowledge of a patient’s ErbB2 status could help physi-
cians identify the most appropriate treatment. Our survey
indicates that up to 1 in 4 Asian patients with breast can-
cer potentially could benefit from ErbB2-targeted treat-
ment. In addition, the variability in ErbB2 assessment
methods evident from our survey highlights the need for
Asiancountriestouseastandard,reliablemethodtoassess
ErbB2. Enhanced ErbB2 assessment methods would ena-
ble us to further refine our understanding of the preva-
lenceofErbB2-positive breastcancer inAsia.
To the best of our knowledge, this is the first survey
of ErbB2-positivity results obtained from a large sample
of patients to indicate that the prevalence of ErbB2-posi-
tive breast cancer in Asia is similar to that in Western
countries (range, 18%-25%).
4,5 Notably, this finding is
based on Asian data that were obtained using the more ro-
bust assessment methods, IHC3þ and FISH.
32,33
Because the prevalence of ErbB2-positive tumors is not
apparently higher in Asia, alternative reasons for the low
breast cancer survival rate should be explored. Possible
reasons include advanced stage at diagnosis
3,34; younger
patients (aged <50 years; associated with more aggressive
Review Article
5352 Cancer December 1, 2010Table 2. Description of Human Epidermal Growth Factor Receptor-Related Gene 2 (ErbB2) Assessment in 22 Studies Reporting
ErbB2-Positive Breast Cancer in Asia
Percentage of Patients (No./Total No.)
Study ErbB2 Assessment IHC21 and IHC31
a IHC31
b FISH
India
Bhamrah 2008
27 IHC: antibody, NR 28.6 (60/210)
c,d NR NR
Meenakshi 2003
17 IHC2þ, IHC3þ: antibody,
in-house monoclonal (CIBCgp185)
25.2 (32/127) 15.7 (20/127) NR
Korea
Kim 2006
14 IHC3þ:  10% cells positive; antibody,
Dako (Glostrup, Denmark)
NR 25 (194/776) NR
Korean Breast Cancer
Society 2006
24
IHC2þ, IHC3þ; antibody: NR 36.9 (1594/4319) 19.8 (854/4319) NR
Park 2003
19 FISH: signal  2-fold centromere region
of chromosome 17; CISH: gene copy >4
NR NR 24.5 (46/188)
Park & Han, 2004
18 IHC2þ, IHC3þ: antibodies, HercepTest
(Dako), rabbit anti-c-ErbB2 (Zymed,
South San Francisco, Calif), mouse
anti-c-ErbB2 (Zymed); FISH:
criteria not reported in English
17.9-22.7 (40/188)
e 6.1-14.4 (21/188)
e 24-28 (73/261)
e,f
Shin 2006
22 IHC2þ, IHC3þ: antibody, NR 51.5 (1131/2196) NR NR
Malaysia
Shahrun 2008
30 NR 44.4 (133/300)
c,g NR NR
Tan & Yip, 2008
31 IHC2þ, IHC3þ: antibody, Dako 60.6 (238/393)
c 34.5 (136/393)
c NR
Singapore
Fernandopulle 2006
12 IHC2þ, IHC3þ: antibody, rabbit
polyclonal (A0485; Dako)
29.6 (16/54) NR NR
Selvarajan 2006
20 IHC2þ, IHC3þ: antibody, rabbit polyclonal,
Dako (A0485; Dako); performed on
standard sections and TMA
21.2 (39/184) 12.5 (23/184)
h NR
Selvarajan 2006
21 IHC2þ, IHC3þ: antibody, rabbit
polyclonal (Dako)
34.3 (110/321) NR NR
Tan 2008
23 IHC2þ, IHC3þ: antibody: SP3, Lab
Vision (Thermo Fisher Scientific, Waltham,
Mass); FISH: signal  2.2-fold centromere
region of chromosome 17 (PathVysion,
Des Plaines, Ill)
19 (27/142) 11.3 (16/142) 37.9 (55/145)
Zhang 2003
26 IHC2þ, IHC3þ: antibody, HercepTest; FISH:
signal  2-fold centromere region
of chromosome 17 (PathVysion)
25 (23/92) 15.2 (14/92) 23 (20/87)
Taiwan
Chen 2008
11 IHC3þ: antibody, HercepTest NR 19 (12/63) NR
Huang 2008
13 NR 64.6 (124/192)
g NR NR
Lin 2007
16 NR 27.7 (28/101)
g NR NR
Lin 2009
15 IHC3þ: antibody, polyclonal (Dako); IHC2þ:
confirmation by FISH (signal  2-fold
centromere region of chromosome
17; PathVysion)
NR 20.5 (211/1028)
i NR
Tsai 2001
25 IHC3þ: antibody, HercepTest NR 41.3 (69/167) NR
Thailand
Chearskul 2001
10 IHC2þ: antibody, rabbit polyclonal (Dako) 32.2 (163/506) NR NR
Moohamad 2008
28 IHC: antibody, NR 17.9 (79/442)
g NR NR
The Philippines
Sanchez 2007
29 IHC3þ: antibody, NR NR 20 (466/2333) NR
IHC indicates immunohistochemistry; FISH, fluorescence in situ hybridization; CISH, chromogenic in situ hybridization; TMA, tissue microarray; NR, not
reported.
aCombined results of IHC2þ and IHC3þ were reported (whether separately or together) unless indicated otherwise.
bResults for IHC3þ were reported separately.
cThe number of ErbB2-positive patients was not stated in study but was calculated from the number assessed and prevalence.
dResults are reported as a range.
eThis study used 3 antibodies; results using the HercepTest are shown.
fThis study used FISH in 3 separate TMAs; results from the largest sample (N¼261) are shown.
gIHC results were reported as positive, but criteria were not specified.
hResults for standard sections.
iIncluded IHC2þ confirmed by FISH (50 of 211).tumors)
3,35; higher prevalence of estrogen or progesterone
receptor-negative tumors, which are less responsive to en-
docrinetherapies
3,36; and thecostand availabilityof treat-
ments, including those thattargetErbB2.
3,34
In our survey, we observed considerable variability in
ErbB2 assessment methods. The most common method
was IHC; however, many factors contribute to variability
in IHC results, including the antibody used
4,9 and the
grading criteria.
9 The relatively small size of many Asian
laboratories also may have contributed to the variability we
observed. Indeed, the concordance in IHC results between
small, local laboratories and high-throughput, central labo-
ratoriescanbeunacceptablylow.
9
We also observed great variability in how IHC
results were reported. Many studies reported both
IHC2þ and IHC3þ staining separately. However,
although some categorized both IHC2þ and IHC3þ
staining as positive,
12,17,18,20,21 others categorized only
IHC3þ staining as positive.
11,14,25,29 Recent guidelines
that were published jointly by the American Society for
Clinical Oncology and the College of American Patholo-
gists (ASCO/CAP) recommend reporting IHC2þ and
IHC3þstainingseparatelyand confirmingtheErbB2sta-
tusof IHC2þ tumorsby FISH.
9 These recommendations
arebasedonthepoorconcordancebetweenIHC2þstain-
ing and gene amplification by FISH.
4,9,32,33 Among the
studies in our survey, only 5 used FISH to determine or
confirm ErbB2 status.
15,18,19,26,31 Not surprisingly, these
studies were conducted in Korea, Singapore, and Taiwan,
countries that are able to fund this more expensive
method.
Despite the apparent similarity in the prevalence of
ErbB2-positive breast cancer in Asian and Western coun-
tries, many Asian patients will not have the same opportu-
nity as Western patients to receive ErbB2-targeted
treatment. ErbB2-positive tumors respond well to ErbB2-
targeted treatments,
6 but these treatments are expensive
and, thus, may not be available to many Asian patients
(Table 4). Without subsidies, many Asian patients with
ErbB2-positive breast cancer may not be able to afford
ErbB2-targeted treatments, which in turn, may reduce the
incentive for ErbB2 assessment. Individual countries need
to weigh the costs of ErbB2 assessment and treatment
with the potential benefit for patients. Because our survey
suggests that the prevalence of ErbB2-positive tumors is
not relatedtocountryincomelevel,atleastthereis no epi-
demiologic justification for restricting ErbB2 assessment
and treatmentinlowerincomecountries.
Worldwide standardization of ErbB2 assessment is
an important goal not only for obtaining unbiased data
on the prevalence of ErbB2-positive breast cancer but also
to ensure that patients receive the most appropriate treat-
ment. Ideally, a standardized assessment method would
adhere to the ASCO/CAP guidelines.
9 However, we must
Figure 1. The median prevalence of human epidermal growth
factor receptor-related gene 2 (ErbB2)-positive breast cancer
is shown. Solid columns indicate 7 Asian countries; open col-
umns, high-income countries; hatched columns, low-income/
middle-income countries. The number of studies and the
number of patients are shown within and beneath each col-
umn, respectively. IHC indicates immunohistochemistry; FISH,
fluorescence in situ hybridization.
Table 3. Prevalence of Human Epidermal Growth Factor
Receptor-Related Gene 2-Positive Breast Cancer in Asia
ErbB2 Assessment Method
Characteristic IHC21 and 31
a IHC31
b FISH
Studies using
method, no.
c
16 12 4
ErbB2-positive patients,
no./total no.
c
3837/9767 2036/9812 194/681
ErbB2-positive prevalence, %
Minimum 17.9 6.1 23
Maximum 64.6 41.3 37.9
Median 29.1 19.4 25.3
Mean6SD 33.7 14.5 20.4 9.3 27.9 6.8
ErbB2 indicates human epidermal growth factor receptor-related gene 2;
IHC, immunohistochemistry; FISH, fluorescence in situ hybridization; SD,
standard deviation.
aEither combined IHC2þ and IHC3þ (whether reported separately or to-
gether) or IHC results were reported as positive, but criteria were not
specified.
bResults for IHC3þ were reported separately.
cBecause some studies used more than 1 ErbB2 assessment method, the
apparent total number of studies and patients (ie, the sum of IHC2þ/
IHC3þ,I H C3 þ, and FISH shown in this table) is greater than the actual
number.
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tions are not practical in many lower income countries.
9
We believe that greater standardization of ErbB2 assess-
ment is particularly needed in the low or middle-income
countries that were included in our study (India, Malay-
sia, Thailand, and the Philippines)(Table 4). The Breast
Health Global Initiative recognizes that the costs of
ErbB2 assessment, especially FISH, and ErbB2-targeted
therapies are ‘‘prohibitively expensive’’ in countries with
limited resources.
37 Because ErbB2 assessment is not rou-
tine in many Asian countries, it would be beneficial, if not
prudent, to provide pathologists with a standardized pro-
tocol and regular validation testing. Given the impact of
pathologist and laboratory experience on ErbB2 results,
smaller Asian countries also might consider establishing a
central laboratory fornationalErbB2assessment.
Oursurveyhasstrengthsandlimitations.Webelieve
that our conclusions regarding the prevalence of ErbB2-
positive breast cancer and ErbB2 assessment methods in
Asia are strengthened by the use of data from 22 studies
involving more than 14,000 patients in 7 Asian countries
that vary in ethnicity, size, and economic status. In addi-
tion, as experts in our respective countries, we were able to
includedatafromlocallanguagejournalsandconferences,
which are not readily available from the MEDLINE data-
base. However, we recognize that our survey does have
limitations. We did not perform a comprehensive, sys-
tematic literature review; rather, we chose to limit the
numberofstudiesweincludedfromeachcountrytoavoid
over-representation of larger, wealthier countries with
more available data. For some countries in our survey, the
only available studies that met our criteria were published
as conference abstracts. We chose to include these studies,
despite their preliminary nature, to examine the current
state of ErbB2 assessment and prevalence in these coun-
tries. Although data for Malaysia were limited at the time
of our survey, the prevalence of ErbB2 positivity reported
in a recent article is consistent with the prevalence we
obtained.
38 Also, although our survey included data from
7 countries, we did not include data from all Asian coun-
tries. Notably, we did not include data from Japan or
China. However, our prevalence results are consistent
with those reported in recent studies from Japan;
39,40
(range, 11%-27%)and China
41(20%). Finally, any litera-
ture survey is retrospective in nature and, as we observed,
is subject to data heterogeneity. Among other factors,
referral bias may have affected the prevalence reported by
some researchers, particularly those from specialist cen-
ters. Whether the data in our selected studies are represen-
tative of the wider population of breast cancer patients in
these countries cannot be determined until further studies
are conducted. Nevertheless, as regional breast cancer
experts, we believe the available data, although limited,
areconsistent withourclinical experience.
In summary, data on the prevalence of ErbB2-posi-
tive breast cancer in Asia are limited. Nevertheless, our
survey, based on data from 14,398 patients in 7 Asian
countries, indicates that the reported prevalence of
ErbB2-positive breast cancer has varied widely from 6%
to 65%. However, when ErbB2 status was assessed
robustly, the median prevalence, based on data from
10,076 patients in 5 Asian countries, was 19% (IHC3þ)
or 25% (FISH), similar to that in the West. Because
ErbB2 status is predictive of both prognosis and respon-
siveness to targeted therapies, Asian countries should
worktowardstandardizationofErbB2assessment.
Table 4. Availability of Human Epidermal Growth Factor Receptor-Related Gene 2 (ErbB2) Assessment Methods and ErbB2-
Targeted Treatments in 7 Asian Countries
High-Income Countries Low/Middle-Income Countries
Variable Korea Singapore Taiwan India Malaysia Philippines Thailand
IHC testing
Routine? Yes Yes Yes Yes No No No
Standardized? Yes Yes No No No No Partial
FISH testing
Routine? Yes Yes Yes No No No No
Standardized? Partial Partial Partial No No No Partial
ErbB2-targeted treatment
Subsidized? Yes Yes Yes Partial Partial No Partial
IHC indicates immunohistochemistry; FISH, fluorescence in situ hybridization.
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